Get Started Free
Home›Healthcare›Abbott Laboratories
Abbott Laboratories logo
Abbott Laboratories
Healthcare

Abbott Laboratories Company Overview

Abbott Laboratories logo

Abbott Laboratories

● Active
Healthcare · Abbott Park, IL · Est. 1888
Medical DevicesDiagnosticsNutritionHealthcare↗ Website
$198B
Valuation
$22.9B
Revenue
114k+
Employees
1888
Founded

Abbott Laboratories is a global healthcare company that develops and manufactures medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Its portfolio spans the FreeStyle Libre continuous glucose monitoring system — the world's most-used CGM — alongside cardiac devices, point-of-care diagnostics, and infant nutrition brands across 160 countries.

Recent Press
5 items
Press Release·2026-01-22
Abbott Reports Fourth-Quarter and Full-Year 2025 Results Reflecting Double-Digit Earnings Growth
Abbott delivered full-year 2025 adjusted diluted EPS of $5.15, reflecting 10% growth, with total sales of $44.3 billion representing 6.7% organic growth, and provided full-year 2026 guidance of 6.5%–7.5% organic sales growth.
Acquisition·2025-11-20
Abbott to Acquire Exact Sciences, Leader in Cancer Diagnostics, in Transaction Valued at Approximately $16 Billion
Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire the cancer diagnostics leader, enabling Abbott to enter and lead in fast-growing cancer screening segments; the deal is expected to close in Q2 2026.
Press Release·2025-10-15
Abbott Reports Third-Quarter 2025 Results; Reaffirms Full-Year Outlook
Abbott delivered strong Q3 2025 results with 7.5% organic sales growth for its underlying base business, reaffirming its full-year 2025 outlook and demonstrating consistent performance across its diagnostics, medical devices, and nutrition segments.
Press Release·2025-08-19
Abbott Announces Plans to Build New Cardiovascular Device Manufacturing Facility in Georgia
Abbott announced plans to construct a new cardiovascular device manufacturing facility in Georgia to support growing demand for its heart failure and structural heart products, with the facility expected to be completed in 2028.
Press Release·2025-07-17
Abbott Reports Second-Quarter 2025 Results
Abbott reported Q2 2025 results with strong organic sales growth across its core business segments and projected full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, of 7.5% to 8.0%.
Company History
10 milestones
Dr. Wallace Calvin Abbott, a physician frustrated with the unreliable quality of drug-filled "dosimetric granules," founded the company to produce reliable, accurately dosed medicines — establishing a quality-first ethos that has remained central to Abbott's identity for over 135 years.

Abbott Laboratories Organization Structure & Team

Org Chart
114,000 employees · Click a leader to explore their team
83,600 across 12 departments
Chief Executive Officer
Robert Ford
Philip Boudreau — Departments
· 83600 people across 12 depts

Abbott Laboratories Financials, Revenue & Market Share

Annual Revenue
$22.9B
+5% vs prior year
YoY Growth
+5%
From $20.2B to $22.9B
Revenue / Employee
$192K
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$20.2B
$43.7B
$20.3B
$21.9B
$22.9B
Market Share
Global Continuous Glucose Monitoring
42%
share
Abbott Laboratories
42%
Dexcom
38%
Medtronic
12%
Senseonics
4%
Others
4%
$450B
TAM
$120B
SAM
$21.9B
SOM
Revenue Streams
Medical Devices48%
Diagnostics31%
Nutrition14%
Established Pharmaceuticals7%
Business Units
Medical Devices48%
The largest segment driven by FreeStyle Libre ($6.4B in 2024, +22% YoY), cardiac rhythm management (Aveir leading the leadless category), and electrophysiology (Volt PFA entering the fast-growing ablation market). Target of $10B+ in medical devices by 2027.
Diagnostics31%
Core laboratory (Alinity systems), point-of-care (i-STAT handheld, ID NOW molecular), and rapid testing platforms. Revenue normalized from $16B+ COVID peak (2021–2022) to baseline ~$6.8B (2024) as pandemic antigen test demand subsided.
Nutrition14%
Pediatric (Similac, PediaSure, Pedialyte) and adult (Ensure, Glucerna, ZonePerfect) nutrition franchises with stable recurring revenue and strong brand loyalty — recovering U.S. Similac market share after the 2022 manufacturing shutdown at Sturgis, MI.
Established Pharmaceuticals7%
Branded generic portfolio in 100+ emerging markets providing profitable, slow-growth recurring revenue with low capital intensity — managed as a cash-generative business unit funding R&D investment in Abbott's device and diagnostics growth segments.

Abbott Laboratories Internal Tools & Processes

Internal Tools
12 departments
Diabetes Care & FreeStyle Libre8200 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Regulatory
FDA QSR (21 CFR Part 820)
Compliant
Abbott's medical device manufacturing facilities in Alameda CA, Plano TX, and Clonmel Ireland operate under FDA 21 CFR Part 820 Quality System Regulation, governing production controls, complaint handling, and corrective actions for Class II and Class III devices including FreeStyle Libre CGM sensors and MitraClip cardiac repair systems.
Quality
ISO 13485
Certified
Abbott holds ISO 13485 quality management system certification across its global medical device, diagnostics, and nutrition manufacturing network — a prerequisite for CE Mark approval in Europe and regulatory acceptance in over 60 countries where Abbott markets FreeStyle Libre, Alinity, and cardiac rhythm management products.
Regulatory
CLIA (Clinical Laboratory Improvement Amendments)
Compliant
Abbott's point-of-care diagnostics products including i-STAT and ID NOW comply with CLIA requirements for laboratory testing performed outside traditional hospital laboratories, enabling hospital bedside, emergency department, and pharmacy-based testing that is central to Abbott's distributed diagnostics strategy.
Regulatory
EU MDR 2017/745
Compliant
Abbott has completed EU MDR technical file transitions for FreeStyle Libre 3, MitraClip, Aveir leadless pacemakers, and Alinity laboratory systems, complying with the heightened clinical evidence, UDI labeling, and post-market surveillance requirements under the 2017 Medical Device Regulation.
Privacy
HIPAA
Compliant
Abbott's LibreView cloud platform for FreeStyle Libre CGM data, the Abbott myFreeStyle app, and remote cardiac monitoring services comply with HIPAA Privacy and Security Rules for transmission, storage, and clinical sharing of protected glucose and cardiac health data for diabetes and cardiac patients.
Quality
ISO 15189
Compliant
Abbott's Alinity laboratory systems are designed and validated to support ISO 15189 accreditation at hospital core laboratories worldwide, ensuring that clinical chemistry, immunoassay, hematology, and molecular results produced on Abbott instruments meet international standards for medical laboratory quality and competence.
Environmental
ISO 14001
Certified
Abbott's major manufacturing facilities including Sturgis MI (nutrition), Clonmel Ireland (diagnostics), and Alameda CA (medical devices) hold ISO 14001 environmental management certification, supporting Abbott's 2030 sustainability goals for 25% reduction in carbon emissions and 100% renewable electricity at key sites.
Regulatory
Sunshine Act (Open Payments)
Compliant
Abbott annually discloses all payments to U.S. physicians and teaching hospitals — covering device training fees, consulting arrangements, research grants, and clinical education programs for FreeStyle Libre, MitraClip, and CRM products — through the CMS Open Payments database per the Physician Payments Sunshine Act.
Regulatory
IEC 62304
Compliant
Abbott applies IEC 62304 software lifecycle standards to all medical device software including the LibreView data platform, FreeStyle Libre 3 app algorithms, i-STAT analyzer firmware, Aveir pacemaker control software, and Alinity instrument operating software, ensuring rigorous safety classification and verification.
Regulatory
Codex Alimentarius (CAC/RCP 1)
Compliant
Abbott's Nutrition division — manufacturing Similac, Ensure, and Glucerna — complies with Codex Alimentarius food safety standards and FAO/WHO guidelines for infant formula and adult nutritional products, ensuring safe formulation and manufacturing practices are maintained across Abbott's global nutrition production network in the U.S., Ireland, and Southeast Asia.

Abbott Laboratories Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Diabetes Care & FreeStyle Libre· 3 roles

Abbott Laboratories Products & Competitors

Product Suite
5 products · select one to explore
Healthcare
Medical Device
FreeStyle Libre 3 Plus
The world's smallest, thinnest CGM sensor — now with real-time alarms.

FreeStyle Libre 3 Plus is a continuous glucose monitoring system featuring a coin-sized sensor worn on the back of the upper arm that automatically measures glucose every minute and streams readings to a smartphone app. Designed for adults and children with diabetes, it delivers real-time glucose values, trend arrows, and customizable alarms without painful fingerstick calibration.

Use Cases
Monitoring glucose trends overnight to detect nocturnal hypoglycemia in Type 1 diabetic patientsSharing real-time glucose data with caregivers and endocrinologists via the LibreLinkUp appIntegrating CGM data into automated insulin delivery systems for closed-loop diabetes management
No image
Key Customers
DXCM
Dexcom
TNDM
Tandem Diabetes
MDT
Medtronic
Competitive Intelligence
VSDexcom G7
THEM

Dexcom G7 is a CGM system featuring a fully disposable, all-in-one sensor-transmitter worn on the abdomen or upper arm, offering a 10-day wear period and direct-to-Apple-Watch streaming for real-time glucose monitoring.

EDGE

Thinner sensor profile and longer 15-day wear duration vs. Dexcom G7's 10-day limit

VSMedtronic Guardian 4
THEM

Medtronic Guardian 4 is the CGM sensor integrated with the MiniMed 780G hybrid closed-loop insulin pump system, designed specifically for automated insulin delivery rather than standalone glucose monitoring.

EDGE

Works independently of a pump with broader smartphone compatibility, no fingerstick calibration required

VSSenseonics Eversense 365
THEM

Senseonics Eversense 365 is an implantable CGM sensor placed under the skin by a clinician and lasting up to 365 days, transmitting glucose readings via an external wearable smart transmitter.

EDGE

No implant procedure needed — simple patient self-application every 15 days

Related Companies

Eli Lilly logo
Eli Lilly
Healthcare
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets medicines across diabetes, oncology, immunology, and neuroscience. Its GLP-1 receptor agonist portfolio — Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity — drove record revenue growth and positioned Lilly as one of the world's most valuable pharmaceutical companies.
Agilent Technologies logo
Agilent Technologies
Healthcare
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical analysis, providing instruments, software, services, and consumables for laboratories worldwide. Its customers include pharmaceutical companies, academic research institutions, environmental labs, and food safety organizations that rely on Agilent's measurement science for analysis, testing, and compliance workflows.
Thermo Fisher Scientific logo
Thermo Fisher Scientific
Healthcare
Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services for scientific research, bioprocessing, clinical diagnostics, and pharmaceutical manufacturing. With over $44B in annual revenue, Thermo Fisher serves pharmaceutical and biotech companies, academic research institutions, clinical laboratories, and government agencies with an unmatched portfolio spanning mass spectrometry, chromatography, cell culture, genetic analysis, and laboratory equipment.
Medtronic logo
Medtronic
Healthcare
Medtronic is the world's largest standalone medical device company, developing therapies and diagnostics across cardiac rhythm management, surgical robotics, neuromodulation, diabetes technology, and endoscopy. Its portfolio spans implantable cardiac monitors, transcatheter pacemakers, robotic surgery platforms, and closed-loop insulin delivery systems used in over 150 countries.
Stryker Corporation logo
Stryker Corporation
Healthcare
Stryker is one of the world's leading medical technology companies, offering a broad portfolio of innovative products and services in orthopedics, medical and surgical equipment, and neurotechnology. The company serves surgeons, hospitals, and healthcare systems across 75 countries with products ranging from joint replacement implants and surgical robots to emergency medical equipment.
Johnson & Johnson logo
Johnson & Johnson
Healthcare
Johnson & Johnson is one of the world's largest healthcare companies, operating across two segments — Innovative Medicine, which develops and markets prescription pharmaceuticals for oncology, immunology, neuroscience, and cardiovascular diseases, and MedTech, which produces surgical robotics, orthopedics, cardiovascular devices, and vision care products. After spinning off its consumer health division as Kenvue in 2023, J&J focuses exclusively on innovative medicine and medical technology.